|
The hypertension
drug ramipril reduces the risk of death from heart failure, according
to a study reported in the Feb. 24 rapid access issue of the Circulation.
Ramipril,
an ACE inhibitor, reduced the rate of heart failure by a significant
22 percent in the 8,315 patients studied who did not suffer a
heart attack. Patients who received the drug also had a lower
rate of hospitalization and death because of heart failure.
Among the
1,029 people studied who had a heart attack, those taking ramipril
had a 13 percent lower rate of heart failure, although the researchers
said this finding was not statistically significant.
"This
trial extends the benefits of ACE inhibitors beyond what has been
previously proven," said lead author Dr. Malcolm Arnold,
a professor at the University of Western Ontario and a cardiologist.
"It shows, for the first time, that heart failure can be
prevented in a broad range of high risk patients."
In an accompanying
editorial, Jennifer V. Linseman, and Dr. Michael R. Bristow, of
the University of Colorado Health Sciences Center in Denver, said
the results are encouraging, but should still be viewed with some
caution.
"These
data support the idea that ACE inhibitors exert a measurable cardiovascular-protective
effect in a broad range of patients at high-risk of cardiovascular
complications, and these effects are additional to and independent
of blood pressure lowering," wrote Linseman and Bristow.
Other sources: American
Heart Association |